BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28188816)

  • 1. A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment.
    Dilly SJ; Clark AJ; Marsh A; Mitchell DA; Cain R; Fishwick CWG; Taylor PC
    Cancer Lett; 2017 May; 393():16-21. PubMed ID: 28188816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
    Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
    Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitor: a tool to investigate the role of type 10 in Alzheimer's disease and prostate cancer.
    Ayan D; Maltais R; Poirier D
    ChemMedChem; 2012 Jul; 7(7):1181-4. PubMed ID: 22674910
    [No Abstract]   [Full Text] [Related]  

  • 5. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
    Etani T; Suzuki T; Naiki T; Naiki-Ito A; Ando R; Iida K; Kawai N; Tozawa K; Miyata N; Kohri K; Takahashi S
    Oncotarget; 2015 Feb; 6(5):2865-78. PubMed ID: 25605246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 16-Picolyl-androsterone derivative exhibits potent 17β-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies.
    Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
    J Steroid Biochem Mol Biol; 2021 Jun; 210():105846. PubMed ID: 33609690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
    Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
    Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.
    Kissinger CR; Rejto PA; Pelletier LA; Thomson JA; Showalter RE; Abreo MA; Agree CS; Margosiak S; Meng JJ; Aust RM; Vanderpool D; Li B; Tempczyk-Russell A; Villafranca JE
    J Mol Biol; 2004 Sep; 342(3):943-52. PubMed ID: 15342248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
    Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
    Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts.
    Cattaruzza L; Fregona D; Mongiat M; Ronconi L; Fassina A; Colombatti A; Aldinucci D
    Int J Cancer; 2011 Jan; 128(1):206-15. PubMed ID: 20209498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct antiproliferative effect of nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors in vitro.
    Berényi Á; Frotscher M; Marchais-Oberwinkler S; Hartmann RW; Minorics R; Ocsovszki I; Falkay G; Zupkó I
    J Enzyme Inhib Med Chem; 2013 Aug; 28(4):695-703. PubMed ID: 22471733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
    Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
    PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
    Sargeant AM; Rengel RC; Kulp SK; Klein RD; Clinton SK; Wang YC; Chen CS
    Cancer Res; 2008 May; 68(10):3999-4009. PubMed ID: 18483287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
    Harada K; Kubo H; Tomigahara Y; Nishioka K; Takahashi J; Momose M; Inoue S; Kojima A
    Bioorg Med Chem Lett; 2010 Jan; 20(1):272-5. PubMed ID: 19954971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis inducer in MCF-7 human breast cancer.
    Jiang W; Li X; Li T; Wang H; Shi W; Qi P; Li C; Chen J; Bao J; Huang G; Wang Y
    Int J Oncol; 2017 Mar; 50(3):823-834. PubMed ID: 28197631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β.
    Sharma V; Verma V; Lal N; Yadav SK; Sarkar S; Mandalapu D; Porwal K; Rawat T; Maikhuri JP; Rajender S; Sharma VL; Gupta G
    Mol Carcinog; 2016 Nov; 55(11):1843-1857. PubMed ID: 26599461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
    Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Nkx3.1 enhances 17beta-estradiol anti-tumor action in PC3 human prostate cancer cells.
    Wang P; Liu B; Luo JD; Zhang ZG; Ma Q; Chen ZD
    Asian J Androl; 2007 May; 9(3):353-60. PubMed ID: 17486276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.